For example, it is now becoming clear that adaptive resistance to mitogen-activated protein kinase kinase enzyme inhibitors (MEK-Is), anaplastic lymphoma kinase inhibitors (ALK-Is), or B-Raf proto-oncogene, serine/threonine kinase inhibitors (BRAF-Is) in many different cancers is driven by the up-regulation of multiple RTKs rendering inhibition of any one RTK ineffective in overcoming the resistance (Caunt et al., 2015; Duncan et al., 2012; Dardaei et al., 2018). Here, BRAF is linked to cancer.